{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Grunwald MR"],"funding":["Forma Therapeutics","Incyte","Rigel","Takeda","Shire","Incyte Corporation","Sunesis Pharmaceuticals, Inc","BMS","TG Therapeutics, Inc","Alexion Pharmaceuticals, Inc","Genentech, Inc","Syntimmune","Roche","Janssen","CTI","NCI NIH HHS","Celgene Corporation","Protalex","Astex Therapeutics"],"pagination":["219-225"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8895348"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(4)"],"pubmed_abstract":["<h4>Background</h4>Polycythemia vera (PV) is associated with increased blood cell counts, risk of thrombosis, and symptoms including fatigue and pruritus. National guidelines support the use of hydroxyurea (HU) in high-risk patients or those with some other clinical indication for cytoreduction.<h4>Patients and methods</h4>REVEAL is a prospective, observational study designed to collect data pertaining to demographics, disease burden, clinical management, patient-reported outcomes, and health care resource utilization of patients with PV in the United States. In this analysis, HU treatment patterns and outcomes were assessed from 6 months prior to enrollment to the time of discontinuation, death, or data cutoff.<h4>Results</h4>Of the 1381 patients who received HU for ≥ 3 months, the median"],"journal":["Clinical lymphoma, myeloma & leukemia"],"pubmed_title":["Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study."],"pmcid":["PMC8895348"],"funding_grant_id":["P30 CA054174"],"pubmed_authors":["Oh ST","Kuter DJ","Grunwald MR","Burke JM","Savona MR","Colucci P","Parasuraman S","Mesa R","Stein B","Walshauser MA","Gerds AT","Altomare I","Paranagama D"],"additional_accession":[]},"is_claimable":false,"name":"Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study.","description":"<h4>Background</h4>Polycythemia vera (PV) is associated with increased blood cell counts, risk of thrombosis, and symptoms including fatigue and pruritus. National guidelines support the use of hydroxyurea (HU) in high-risk patients or those with some other clinical indication for cytoreduction.<h4>Patients and methods</h4>REVEAL is a prospective, observational study designed to collect data pertaining to demographics, disease burden, clinical management, patient-reported outcomes, and health care resource utilization of patients with PV in the United States. In this analysis, HU treatment patterns and outcomes were assessed from 6 months prior to enrollment to the time of discontinuation, death, or data cutoff.<h4>Results</h4>Of the 1381 patients who received HU for ≥ 3 months, the median","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Apr","modification":"2025-04-18T12:11:44.079Z","creation":"2025-04-06T21:51:15.207Z"},"accession":"S-EPMC8895348","cross_references":{"pubmed":["32063527"],"doi":["10.1016/j.clml.2019.09.601"]}}